Extended-Spectrum Beta-Lactamase and AmpC Beta-lactamase Mediated Resistance in Escherichia coli from Clinical Sources

Agbagwa OE^1, and Aminofifori J¹

¹Department of Microbiology Faculty of Science University of Port Harcourt, Rivers State Nigeria, P.M.B. 5323 East-West Road Choba

Cite this paper:
Agbagwa OE and Aminofifori J. Extended-Spectrum Beta-Lactamase and AmpC Beta-lactamase Mediated Resistance in Escherichia coli from Clinical Sources. American Journal of Microbiological Research. 2017; 5(5):107-112. doi: 10.12691/ajmr-5-5-3

Abstract

The development of antibiotic resistance in bacteria following the introduction of antimicrobial agents has emerged as an important medical problem worldwide. Antibiotic resistance has made the treatment of infectious diseases a global challenge. The study was carried out to detect Extended Spectrum Beta-Lactamase (ESBL) and Amp C Beta-lactamase mediated resistance of Escherichia coli. Twelve isolates were collected from the University of Port Harcourt, department of Microbiology; nine out of the 12 were identified to be E. coli after series of biochemical test. Antimicrobial susceptibility testing was carried out on all the isolates using the disc diffusion method. High level of antimicrobial resistance was observed in the test organism against Augmentin and Ampicillin. ESBL preliminary screening, ESBL phenotypic confirmatory test and double disk synergy test was performed on all the isolates to detect ESBL producers. Results obtained from the study showed that 5(55.5%) out of the nine E. coli isolates were confirmed to be ESBL producers. AmpC production was detected in only one of the E. coli isolate which was from wound swab. The study revealed a high rate of ESBL- producing E. coli from clinical specimen. Further studies should be carried out using molecular method to detect ESBL genes and a wider range of E. coli from different sources should be used.

Keywords:
Amp C Antibiotic resistance E. coli Extended Spectrum Beta-Lactamase

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Rajiv, D. Disease, illness, education, public awareness, science and technologyand antimicrobial resistance. 2016.
[2]	Cantón R., Novais A., Valverde A., Machado E., Peixe L., Baquero, F. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect, 2008, 1:44-53.
[3]	Martine´z-Martine´z, L., Herna´ndez-Alle´s, S., Albertı´s, S., Toma´s J., Benedi, V. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob. Agents Chemother, 1996, 40, 342-348.
[4]	Bradford, PA. Extended – spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev, 2001, 14, 933-951.
[5]	Thomson, KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis, 2001, 7, 3-6.
[6]	Kalayama, Y., Zhang, HZ., Chambers, HF. PBP mutations producing very-high- level resistance in beta-lactamase. Antimicrobial Agents Chem. 2004, 48, 453-459.
[7]	Davies, TA., Shang W., Bush K., Flamm, RK. Activity of Imepenem and comparator beta-lactam agent clinical isolates of streptococcus pneumonia with defined motivations in the penicillin binding domain of pbp2b and pbp2x. Journal of A.M chemother. 2008, 6(3); 751-753.
[8]	Stratton, CW. Mechanisms of bacterial resistance to antimicrobial agents. 2000.
[9]	Coudron, PE. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. Journal of Clinical Microbiology, 2005, 43:416-437.
[10]	Cheesbrough M. District laboratory practice in tropical countries, part 2. Cambridge University Press, Cambridge, 2005, 159-162.
[11]	Krieg, NR and Holt, JW. Bergey’s Manual of bacteriology, 9th edition, Williams and Wilkins, Baltimore. 1994.
[12]	CLSI. Performance Standards for Antimicrobial Susceptibility Testing. In: Twenty-third Informational Supplement. CLSI Document M100-S23, Pennsylvania. Clinical and Laboratory Standards Institute, 2013, 34-190.
[13]	Gayathri, G.,Kathireshan, AK., Balagurunathan, R. Prevalence of extended spectrum Beta Lactamases in Uropathogenic E. coli and Klebsiella species in a Chennai Suburban Tertiary Care Hospital and its Antibiogram Pattern. Research Journal of Microbiology, 2011, 6: 796-804.
[14]	Giriyapur, RS., Nandihal, NW., Krishna, BVS., Patil, AB., Chandrasekhar, MR. Comparison of Disc Diffusion Methods for the Detection of Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae. Journal of Laboratory Physician, 2011, 3: 33-36.
[15]	Shahanara, B., Abdus Salam, MD., Faisal Alam, KH., Nurjaham, B., Harsan, JA. Detection of extended spectrum beta- lactamase in Pseudomonas spp isolated from two tertiary hospitals in Bangladesh. 2013, BMC Research Notes, 6, 1-6.
[16]	Altayar. MA., Thokar. MA., Mohammad. MA. Extended spectrum beta-lactamase- producing Escherichia coli in clinical isolates in benghazi, libya: phenotypic detection and antimicrobial susceptibility pattern. Medical Journal of Islamic World Academy of Sciences 2012, 20:49-56.
[17]	Ahmed BO, Omar AO, Asghar AH, Elhassan MM. Increasing Prevalence of ESBL- Producing Enterobacteriaceae in Sudan Community Patients with UTIs. Egyptian Academic Journal of Biological Science. 2013; 5: 17-24.
[18]	Metri, BC., Jyothi, P., Peerapur, V. The prevalence of ESBL among enterobacteriaceae in tertiary care hospital of North Karnataka India. J.Clin. Diagn. Res, 2011, 5:470-475.
[19]	Amita, J., Indranil, R., Mahenda, KG., Mala, K., Agarwal, SK. Prevalence of extended spectrum betalactamase producing Gram negative bacteriamin septicaemic neonates in a tertiary care hospital. Journal of medical microbiology, 2003, 52: 421-425.
[20]	Wadekar, MD., Anuradha K., Venkatesha D. Phenotypic detection of ESBL and MBL in clinical isolates of Enterobacteriaceae. Into.J.Current.Red.Aca.Rev; 2013, 1: 89-95.
[21]	Bazzaz, BS., Naderinasab, M., Mohamadpoor, AH., Farshahzadeh, Z., Ahmadi, S., Yousefi, F. The prevalence of extended spectrum Beta-lactamase producing Escherichia coli and Klebsiella pneumonia among clinical isolates from a general hospital in Iran. Acta Microbiologica et Immunologica Hungarica, 2009, 56: 89-99.
[22]	Doi, Y. and Paterson, DL. Detection of plasmid-mediated class C beta-lactamases. Int J Infect Dis, 2007, 11: 191-7.
[23]	Shayan, S. and Bokaeian, M. Detection of ESBL – and AmpC- producing E. coli isolates from urinary tract infections. Advanced biomedical research, 2015, 4: 220-223.